We are interested in the mechanisms that regulate telomere length in normal and cancer cells. Telomeres are the structures at chromosome ends that provide stability to chromosomes and allow the complete replication of the ends. Broken chromosomes that lack telomeres undergo fusions that lead to karyotypic abnormality and chromosome instability; characteristics common in cancer cells. Telomere length is normally maintained as an equilibrium between processes that lengthen and those that shorten telomeres. The ribonucleoprotein DNA polymerase, telomerase, specifically elongates telomeres in vivo. Recent evidence suggests that telomerase may be required for the growth of tumors. Thus, telomerase has been proposed as a new target for cancer chemotherapy. To determine if the absence of telomerase inhibits tumor growth or tumor progression, we are generating a telomerase null mouse in collaboration with Dr. Ronald DePinho. The experiments proposed here will determine whether telomerase is required for tumor induction and for sustained tumor growth. If telomerase is required for sustained tumor growth, tumors lacking telomerase will progress more slowly or perhaps regress, compared to telomerase expressing tumors. Thus or studies in mice will determine whether anti-telomerase drugs may be effective cancer therapeutics. We will look directly for potential recombination mediated telomerase bypass pathways that may lead to telomerase independent tumors. Finally, a telomerase null mouse will help identify potential side effects of telomerase inhibitors, which will need to be addressed in pre-clinical studies.
| Tramentozzi, Elisa; Ferraro, Paola; Hossain, Manzar et al. (2018) The dNTP triphosphohydrolase activity of SAMHD1 persists during S-phase when the enzyme is phosphorylated at T592. Cell Cycle 17:1102-1114 |
| Arun, Gayatri; Diermeier, Sarah D; Spector, David L (2018) Therapeutic Targeting of Long Non-Coding RNAs in Cancer. Trends Mol Med 24:257-277 |
| Tarumoto, Yusuke; Lu, Bin; Somerville, Tim D D et al. (2018) LKB1, Salt-Inducible Kinases, and MEF2C Are Linked Dependencies in Acute Myeloid Leukemia. Mol Cell 69:1017-1027.e6 |
| Xu, Yali; Milazzo, Joseph P; Somerville, Tim D D et al. (2018) A TFIID-SAGA Perturbation that Targets MYB and Suppresses Acute Myeloid Leukemia. Cancer Cell 33:13-28.e8 |
| Huang, Yu-Han; Klingbeil, Olaf; He, Xue-Yan et al. (2018) POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer. Genes Dev 32:915-928 |
| Livshits, Geulah; Alonso-Curbelo, Direna; Morris 4th, John P et al. (2018) Arid1a restrains Kras-dependent changes in acinar cell identity. Elife 7: |
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
| Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804 |
| Banito, Ana; Li, Xiang; Laporte, Aimée N et al. (2018) The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell 34:346-348 |
| Skucha, Anna; Ebner, Jessica; Schmöllerl, Johannes et al. (2018) MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nat Commun 9:1983 |
Showing the most recent 10 out of 610 publications
